ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Income Statement
NYSEARCA:ATNM - NYSE Arca - US00507W2061 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 81.00K | 1.03M | 1.14M | 0.00 | |||
| Operating Expenses | 42.12M | 52.00M | 35.13M | 26.11M | 22.39M | |||
| Research and Development | 29.88M | 38.49M | 22.99M | 17.94M | 16.05M | |||
| Selling, General, and Administrative Expenses | 12.04M | 13.30M | 11.99M | 8.06M | 6.29M | |||
| Operating Income | -42.12M | -51.92M | -34.10M | -24.96M | -22.39M | |||
| Interest Income/Expense | 3.88M | 3.10M | 1.09M | 190.00K | 178.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -38.24M | -48.82M | -33.02M | -24.77M | -22.21M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -38.24M | -48.82M | -33.02M | -24.77M | -22.22M | |||
| EBITDA | -41.31M | -51.13M | -33.41M | -24.44M | -21.95M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | |||
| Non GAAP EPS | -1.27 | -1.84 | -1.37 | -1.20 | -2.04 | |||
| Statistics | ||||||||
| Profit Margin | N/A | -60269.14% | -3205.53% | -2165.56% | N/A | |||
| Operating Profit Margin | N/A | -64098.77% | -3311.07% | -2182.17% | N/A | |||
All data in USD